WSWilliam H. Sauer

William H. Sauer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


William H. Sauer has a total of 266 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of Pulsed Field Timing Sequence and Electrode Cooling on Ablation Safety and Efficacy Surrogates: A Preclinical Study

    by Luigi Di Biase, Jonathan Hsu, Rahul Bhardwaj, David Newton, William Maddox, Jorge E. Romero, Tara Gomez, Eric Byun, Qi Chen, Christopher Beeckler, et al.

    BACKGROUND: The variable loop circular catheter has been shown to be a safe, effective pulsed field ablation catheter for atrial fibrillation treatment. After the commercial launch of the initial waveform (Seq1), a new waveform (Seq2 30 mL/min ) was developed that reduces electrode surface temperature and ablation delivery time (20–3.8 seconds). This study compares the safety and efficacy of Seq1 versus Seq2 across 2 irrigation rates and 2 dosing conditions. METHODS: Twenty-four Yorkshire pigs were treated with pulsed field ablation using the variable loop circular catheter. Subjects were randomized into 3 pulse recipe/irrigation arms (Seq1 4 mL/min , Seq1 30 mL/min , and Seq 2 30 mL/min ). Each group was split into a 1× nominal and a 2×-dose group, resulting in 6 total study groups. Animals were monitored for 28±2 days postablation for follow-up remapping procedures before euthanization. Gross necropsy and histopathology were performed on day 28±2. RESULTS: In all groups, 100% acute and chronic pulmonary vein isolation effectiveness was observed, as indicated by transmural, circumferential, pulmonary vein lesions with no evidence of collateral injury. Transmurality in the left atrial appendage, LA roof, and posterior wall was 75% to 100% across all groups and absent at the mitral isthmus. No catheter thrombus/char was observed at Seq2 30 mL/min or Seq1 30 mL/min . With Seq1 4 mL/min , thrombus/char occurred in 25% (1×) and 100% (2×). Hemolysis and myocardial injury marker changes were similar between all groups, with a notable increase in the 2× groups. On echocardiography, Seq2 30 mL/min microbubbles were rated as few or none, while Seq1 4 mL/min and Seq1 30 mL/min were mostly rated moderate or shower. CONCLUSIONS: Consistently durable pulmonary vein isolation was observed across all groups, including Seq1 4 mL/min , Seq2 30 mL/min , and Seq1 30 mL/min across both dosing conditions. Seq2 30 mL/min was associated with a reduced ablation delivery time (3.8 seconds), zero catheter thrombus formation, and few microbubbles. Higher irrigation flow in Seq1 30 mL/min also mitigated catheter thrombus formation but did not reduce microbubble generation.

  • Open Access

    Safety and efficacy of left atrial ablation after percutaneous left atrial appendage occlusion in high-bleeding-risk patients with atrial fibrillation: a multicentre analysis from the PROCEED-AF ablation registry

    by Rachel M Kaplan, Jeanne du Fay de Lavallaz, Christian-Hendrik Heeger, Hakan Oral, Mason Yoder, David Schaack, Julian K Chun, Boris Schmidt, Jeffrey Winterfield, William H Sauer, et al.

    Aims: Patients with left atrial appendage (LAAO) devices are increasingly referred for atrial fibrillation (AF) ablation, yet anticoagulation strategies remain uncertain. The goal of this study was to evaluate the safety and efficacy of catheter ablation for AF in patients with pre-existing LAAO devices and to describe patterns in anticoagulation management after ablation in this unique population. Methods and results: We collected data from 14 centres worldwide on patients with prior LAAO devices undergoing AF ablation. Each site provided clinical characteristics, procedural details, and information on complications and arrhythmia outcomes. Data were aggregated and analysed centrally to evaluate procedural safety, efficacy, and variability in management strategies. A total of 198 patients (age 70 years, 37% female, 42% paroxysmal AF) with prior LAAO were included. Ablation was performed a median of 271 days after LAAO. After ablation, 84% of patients were on oral anticoagulation (OAC), most commonly for 2–3 months. Bleeding complications on OAC occurred in 6.7% of patients at a median of 20 (13, 70) days after ablation. Stroke or TIA occurred in five patients (2.6% of cases) within the follow-up period with two occurrences (1% of cases) the day after ablation. There were two cases of new or worsened peri-device leak after ablation. Conclusion: In a large, international registry of patients undergoing catheter ablation for AF with pre-existing LAAO devices, ablation was feasible, and device related complications were rare. Despite higher bleeding risk in an LAAO population, 84% of patients with prior LAAO tolerated short-term OAC post-ablation with bleeding events at expected rates for this population.

  • Open Access

    Ventricular tachycardia ablation associated abnormalities on FDG PET/CT in patients with suspected cardiac sarcoidosis

    by Brigitte Kazzi, Stephen J Hankinson, Sylvain L Carre, Jon Hainer, Akshay S Desai, Garrick C Stewart, Neal K Lakdawala, Michael M Givertz, Ron Blankstein, Marcelo F Di Carli, et al.


  • Top Cited Papers

    Pulsed field ablation and arcing phenomenon near left atrial appendage occlusion devices: An in vitro study

    by Daniel Campos-Villarreal, Nathaniel A. Steiger, Maxwell Coll, Tessa O’REilly, William H. Sauer


  • Open Access

    Limited association between septal myocardial involvement on PET imaging and conduction disturbance in cardiac sarcoidosis

    by Brigitte Kazzi, Xiaoxiao Qian, Sanjay Divakaran, Usha B. Tedrow, William H. Sauer

  • Open Access

    Thermal preconditioning of targeted tissue enhances pulsed field ablation lesions

    by Daniel Campos-Villarreal, Maxwell Coll, Logan McClennen, Chieko Imamura, Camila C Aragón, Andres F Miranda-Arboleda, Jorge E Romero, Nathaniel A Steiger, William H. Sauer

    Introduction Pulsed field ablation (PFA) is a cardiac ablation modality that induces cell death via irreversible electroporation (IRE) rather than thermal injury. Intrinsic biophysical tissue properties - including temperature and conductivity- can influence PFA lesion formation, however, this phenomenon is not thoroughly characterized. Objective To evaluate the impact of thermal preconditioning on PFA lesion characteristics using a controlled in vitro model. Methods Twenty-millimeter-thick Solanum tuberosum potato slabs were assigned to one of five preconditioning groups: cold (7–10 °C), control (21.5–23 °C), room-temperature soaked (immersed in water at 21.5–23 °C), dry-heated (40 °C), and wet-heated (40 °C water-soaked). Pre-ablation surface temperature was recorded. A monophasic unipolar PFA application was delivered (1750 V, 20 µs pulses, 3 pulses, 1-second interval) using a 3.5 mm electrode catheter. Lesions were stained with 2,3,5-triphenyltetrazolium chloride (TTC) and measured. Results Pre-heating the tissue to 40 °C produced markedly larger lesions than control. Dry-heated samples produced a mean lesion diameter of 34.1 ± 1.7 mm and wet-heated 35.0 ± 1.9 mm, vs. 25.3 ± 2.0 mm in controls (p < 0.001). Lesion depth was also greater in heated tissue (wet-heated 12.23 ± 0.76 mm vs. control 10.7 ± 1.3 mm, p = 0.017). In contrast, cooling the tissue to < 10 °C reduced lesion diameter (23.1 ± 2.3 mm) and depth (9.3 ± 1.0 mm), significantly smaller than controls (both p < 0.01). Room-temperature soaking (RT-soaked) alone did not produce significant change in lesion dimensions. Conclusions In this in vitro model, thermal preconditioning significantly alters PFA lesion formation. Increasing the tissue temperature prior to ablation markedly increases lesion diameter and depth, possibly by lowering the electroporation threshold. These findings suggest that tissue temperature is a tunable factor influencing PFA efficacy. Graphical Abstract


  • Joule Heating and the Apparent Paradox of Nonthermal Ablation

    by William H. Sauer, Maxwell D. Coll

  • Open Access

    Procedural characteristics and clinical outcomes from same-day discharge after pulsed field ablation treatment for atrial fibrillation: an admIRE trial sub-analysis

    by Luigi Di Biase, Vivek Y Reddy, Xiaodong Zhang, David Newton, Sandeep Goyal, Devi Nair, William H Sauer, Vivek Iyer, Christopher F Liu, Jose Osorio, et al.

    Aims: Same-day discharge (SDD) following catheter ablation for atrial fibrillation (AF) yields a promising approach to enhance patient satisfaction and reduce healthcare costs. While prior data support the safety of SDD after radiofrequency ablation, evidence following pulsed field ablation (PFA) remains limited. This sub-analysis of the admIRE trial (NCT05293639) evaluates the safety of SDD compared with overnight stays (ONS) after PFA using a variable-loop circular catheter (VLCC). Methods and results: Baseline and procedural characteristics, safety, and effectiveness were compared between SDD and ONS groups. Primary effectiveness was defined as freedom from composite failure using Kaplan–Meier estimates. Serious adverse events (SAEs) occurring ≤7 days and ≥1 day post-index procedure were assessed. Amongst 277 patients in the admIRE trial, 119 (43.0%) completed SDD, and 158 (57.0%) stayed overnight. The SDD group included fewer patients aged ≥65 years (41.2% vs. 52.5%), shorter fluoroscopy times (4.0 vs. 8.9 min), higher first-pass isolation rates (97.5% vs. 82.9%), and fewer procedural AEs (1.7% vs. 3.8%). More procedures in the SDD group occurred in the morning (63.0% vs. 39.2%). Freedom from primary effectiveness failure was similar (SDD, 75.4% [95% CI 67.4–83.3%] vs. ONS, 74.0% [95% CI 66.4–81.5%]). No significant difference in SAE risk was observed overall [HR, 1.07 (95% CI 0.47–2.44)] or ≤7 days post-procedure [HR, 0.78 (95% CI 0.17–3.49)]. Post-procedural serious cardiac/vascular AE rates were also comparable (SDD, 2.5% vs. ONS, 1.3%). Conclusion: SDD is feasible in a paroxysmal AF population undergoing PFA with the VLCC, demonstrating comparable safety and effectiveness outcomes with overnight hospitalization.


  • Evaluation of variable inter-pulse delay and timing on pulsed field ablation lesion characteristics

    by Nathaniel A. Steiger, Daniel Campos-Villarreal, Logan McClennen, Justin Bilenker, Mark Zurcher, Melvin Lorenzo, Carlos Patino, Carlos Matos, Carolina Hoyas-Ochoa, Usha B. Tedrow, et al.

    Background Irreversible electroporation with pulsed-field ablation (PFA) represents a promising modality via myocyte-selective treatment of arrhythmias. However, aside from voltage, a thorough evaluation of PFA output parameters on lesion characteristics has not been performed. Objective To demonstrate the impact of timing cycle attributes on PFA lesion characteristics using an established in vitro electroporation model. Methods Russet potato slabs underwent unipolar PFA using a 3.5-mm electrode catheter connected to a programmable PFA generator. PFA waveforms were delivered with a train ranging from 1 to 3 biphasic pulses, 1 to 50 cycles, frequency of 50 kHz, inter-pulse delay of 200 to 1310 ms, and with repeated applications using variable inter-application pauses from 5 to 20 s. Experiments were repeated with varying voltage outputs. The slabs were sliced, stained, and measured. Results Increasing number of cycles and number of PFA applications were associated with larger lesions but reached a plateau effect despite increased total energy delivered. There was a linear relationship between increasing inter-pulse delay and depth. There was no change in lesion size with application period. Conclusion Increasing the inter-pulse delay of pulse sequences created deeper lesions despite total energy remaining constant and achieved similar depths compared to pulses that used more cycles and greater number of applications. Modulating inter-pulse delay may be useful for controlling lesion depth without increasing total application energy delivery, which may reduce risks associated with high energy PFA pulses. Further research is required to correlate these in vitro findings with in vivo results and clinical outcomes. Graphical Abstract